Chennai: Glenmark Pharmaceuticals has announced that it would lower the price of its generic version of favipiravir, Fabriflu, to $1 per tablet (around Rs 75), which is being prescribed for restricted emergency use on Covid-19 patients with mild to moderate symptoms.
A typical treatment for favipiravir involves 122 tablets taken over 14 days, which at the earlier rate of Rs 103 per tablet, worked out to a treatment cost of Rs 12,566. Under the new rates, the same treatment would cost Rs 9,150.
Glenmark announced the reduction along with a 1,000-patient post-marketing surveillance study’. Its senior vice president and head-India business, Dr Alok Malik, said it is expected to shed more light on the drug’s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu.
According to Malik, FabiFlu had been launched in India at the lowest market cost compared to its cost in other countries that have approved it.
Glenmark said the reduction in price was due to benefits gained from higher yields and better scale due to both the Active Pharmaceutical Ingredient (API) and formulations being made at Glenmark’s Indian facilities.
Glenmark said they were also conducting another Phase 3 clinical trial to evaluate the efficacy of two antivirals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India.
The combination study, called the FAITH trial, is looking to enroll 158 hospitalized patients of moderate Covid-19 in India.